Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern A M, Wands J R, Friedman P A
Molecular Hepatology Laboratory, Massachusetts General Hospital Cancer Center, Charlestown 02129, USA.
J Clin Invest. 1996 Sep 15;98(6):1313-23. doi: 10.1172/JCI118918.
To characterize genes that become upregulated with malignant transformation of human hepatocytes, a library of monoclonal antibodies was produced against the FOCUS hepatocellular carcinoma cell line. Antibody FB-50 reacted with an antigen that was highly expressed in 4 of 10 primary hepatocellular carcinomas, in all 20 cholangiocarcinomas we studied, and in a variety of transformed cell lines. This antigen was also highly expressed in neoplastic epithelial cells of breast and colon carcinomas in contrast to its low level of expression in normal hepatocytes and in non-neoplastic epithelial cells. Among the normal adult tissues studied, high levels were observed only in proliferating trophoblastic cells of the placenta and in adrenal glands. A 636-bp partial cDNA, isolated from a gamma GT11 expression library generated with HepG2 human hepatoblastoma cells, and a complete cDNA, generated by reverse transcriptase-PCR, identified the antigen as the human form of aspartyl(asparaginyl)beta-hydroxylase. This enzyme catalyzes posttranslational hydroxylation of beta carbons of specific aspartyl and asparaginyl residues in EGF-like domains of certain proteins. Analyses of extracts prepared from several human tumor cell lines compared to their normal tissue counterparts indicate that the increase in hydroxylase, approximately 10-fold, is controlled at the level of transcription and the protein is expressed in an enzymatically active form. In similar analyses, comparing hepatocellular carcinomas to adjacent uninvolved liver from five patients, enzymatic activity was much higher in the tumor tissue from the four patients whose immunoblots revealed increased hydroxylase protein in the malignant tissue. EGF repeats in the extracellular domain of Notch or its homologs contain the consensus sequence for hydroxylation. Deletion mutants lacking this domain are gain-of-function mutants, suggesting that the domain modulates signal transduction by the cytoplasmic domain. While the function imparted by beta hydroxylation is unknown, our studies raise the possibility that beta hydroxylation is regulated in proteins like the mammalian Notch homologs, whose cytoplasmic domains have been shown to be oncogenic.
为了鉴定在人肝细胞恶性转化过程中上调的基因,制备了针对FOCUS肝癌细胞系的单克隆抗体文库。抗体FB-50与一种抗原发生反应,该抗原在10例原发性肝细胞癌中的4例、我们研究的所有20例胆管癌以及多种转化细胞系中高度表达。与正常肝细胞和非肿瘤上皮细胞中低水平表达相比,该抗原在乳腺癌和结肠癌的肿瘤上皮细胞中也高度表达。在所研究的正常成人组织中,仅在胎盘的增殖滋养层细胞和肾上腺中观察到高水平表达。从用人肝癌细胞系HepG2构建的γGT11表达文库中分离出一个636bp的部分cDNA,通过逆转录-聚合酶链反应(RT-PCR)获得一个完整的cDNA,鉴定该抗原为人天冬氨酰(天冬酰胺基)β-羟化酶。这种酶催化某些蛋白质的表皮生长因子(EGF)样结构域中特定天冬氨酰和天冬酰胺基残基β碳的翻译后羟化。对几种人肿瘤细胞系及其正常组织对应物提取物的分析表明,羟化酶增加了约10倍,这是在转录水平受到调控的,并且该蛋白以酶活性形式表达。在类似的分析中,将5例患者的肝细胞癌与其相邻未受累肝脏进行比较,在4例免疫印迹显示恶性组织中羟化酶蛋白增加的患者的肿瘤组织中,酶活性要高得多。Notch或其同源物细胞外结构域中的EGF重复序列包含羟化的共有序列。缺乏该结构域的缺失突变体是功能获得性突变体,这表明该结构域通过细胞质结构域调节信号转导。虽然β羟化赋予的功能尚不清楚,但我们的研究提出了一种可能性,即β羟化在哺乳动物Notch同源物等蛋白质中受到调控,其细胞质结构域已被证明具有致癌性。